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Abstract
Background: B-Acute lymphoblastic leukemia (B-ALL) represents a hematologic malignancy with poor clinical
outcome and low survival rates in adult patients. Remission rates in Hispanic population are almost 30 % lower and
Overall Survival (OS) nearly two years inferior than those reported in other ethnic groups. Only 61 % of Colombian
adult patients with ALL achieve complete remission (CR), median overall survival is 11.3 months and event-free
survival (EFS) is 7.34 months. Identification of prognostic factors is crucial for the application of proper treatment
strategies and subsequently for successful outcome. Our goal was to identify a gene expression signature that
might correlate with response to therapy and evaluate the utility of these as prognostic tool in hispanic patients.
Methods: We included 43 adult patients newly diagnosed with B-ALL. We used microarray analysis in order to
identify genes that distinguish poor from good response to treatment using differential gene expression analysis.
The expression profile was validated by real-time PCR (RT-PCT).
Results: We identified 442 differentially expressed genes between responders and non-responders to induction
treatment. Hierarchical analysis according to the expression of a 7-gene signature revealed 2 subsets of patients
that differed in their clinical characteristics and outcome.
Conclusions: Our study suggests that response to induction treatment and clinical outcome of Hispanic patients
can be predicted from the onset of the disease and that gene expression profiles can be used to stratify patient risk
adequately and accurately. The present study represents the first that shows the gene expression profiling of B-ALL
Colombian adults and its relevance for stratification in the early course of disease.
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Background
Acute lymphoblastic leukemia (ALL) is a hematologic ma-
lignancy involving the bone marrow and other organs due
to uncontrolled proliferation of lymphoblasts that are
characterized by a progressive loss of the ability of differ-
entiation [1]. Although in Colombia ALL is not one of the
most common types of cancer, it represents a public
health problem that requires priority attention because its
incidence and mortality increase annually [2, 3]. ALL is
most common in children under 15 years old than in
adults; however, in adults the disease has a more aggres-
sive behavior than in children [4, 5]. Currently about 90 %
of individuals younger than 15 years achieve complete re-
mission and 70 % are cured of the disease [4], while in
adults, only 75 % reach complete remission and disease
free survival (DFS) does not exceed 30 % [6–8].
Although intensive chemotherapeutic schemes have
been implemented in adults for more than a decade in the
United States and other countries [9–14] and have led to
higher rates of durable remissions in Colombia these
schemes have shown disappointing results with a median
OS of less than 11.3 months, EFS of only 7.34 months,
and only 61 % achieve CR [15]. Interestingly, other Latin
American studies report similar worst survival when
implementing these same regimens [16, 17]. Therefore, it
is interesting to explore the underlying molecular charac-
teristics of the disease in Colombian patients.
Identification of prognostic factors in patients with ALL
is crucial for the proper planning of treatment strategies
and the optimal results of therapy. Currently, in order to
risk -stratify patients with B-ALL, several variables are
considered: 1) demographic characteristics such as age
and gender; 2) leukocyte count at diagnosis of the disease
and infiltration of tumor cells in the central nervous sys-
tem; 3) biological characteristics of tumoral cells including
immunophenotype, cytogenetic, chromosomal transloca-
tions; and 4) Responsiveness to treatment through detec-
tion of (MRD) residual disease using highly sensitive
techniques [18, 19]. Genetic alterations that give rise to
chromosomal rearrangements together with age (younger
or older than 30 years) and white blood cell count
(WBCC) (more or less than 30.000/uL) strongly influence
the survival of patients with ALL [19, 20]. These 3 vari-
ables represent the factors that best determine the prog-
nosis at diagnosis of B-ALL adult patients. However,
approximately 50 % of adults with B-ALL do not have
chromosomal rearrangements and therefore are classified
as standard risk group [21]. It has been reported that this
group of patients is particularly heterogeneous according
to the OS and DFS and that a large number of them
present treatment failure, relapse and death [22]. There-
fore, there is a need to find new genetic markers that can
be detected at diagnosis and at initial treatment stages in
order to increase the accuracy of risk stratification and
treatment allocation and also to minimize both, under and
overtreatment.
In this context, determining the gene expression pro-
file of thousands of genes simultaneously provides an ap-
proximation that enables a better exploration of the
mechanisms of transformation and behavior of malig-
nant cells. Since the development of techniques for the
evaluation of gene expression like cDNA microarrays,
great advances have been made in diagnostic, classifica-
tion and prognosis of cancer in both hematological ma-
lignancies and solid tumors [23–30]. In hematological
neoplasms the study of genes expressed in the disease
versus normal tissue counterpart has elucidated the
mechanisms of pathology, and identified potential points
of therapeutic intervention [31]. Several reports have
shown the ability of gene expression profiles to discrim-
inate between different types of leukemias, including dif-
ferent subsets of acute lymphoblastic leukemia, as well
as different disease outcomes in pediatric ALL groups.
However, research in disease prognosis based on gene
expression profiles specifically in B-ALL affecting adult
patients is poorly explored [26, 27, 32].
The present study compares, for the first time, the gene
expression profiles in diagnostic samples from B-ALL
Colombian adult patients responding or not to induction
therapy. This data represents a potential stratification tool




All patients were recruited at the Colombian National
Cancer Institute and Hospital Universitario San Ignacio
both in Bogota, Colombia. Forty-three samples from
adult patients diagnosed with precursor B-ALL were
analyzed in this study (41 bone marrow (BM) and 2 per-
ipheral blood (PB) samples obtained at diagnosis). Three
normal BM samples were used as control. The diagnosis
of B-ALL was based on morphologic evaluation of bone
marrow aspirate to determine the presence of blasts,
immunophenotyping and cytogenetic analysis of periph-
eral blood (PB) or BM. This study was approved by the
Institutional Review Boards and Ethics Committees of
both, Colombian National Cancer Institute and Hospital
Universitario San Ignacio. Participation was voluntary,
and written informed consent was obtained.
Flow cytometry
Immunophenotype analysis was performed using the
panel of antibodies recommended and standardized by
the European consortium Euroflow [33]. Lymphoblasts
were gated combining 8-color fluorescence for identifi-
cation and phenotypic characterization of B-ALL. Anti-
gens tested included surface CD20, CD58, CD66, CD10,
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CD38, SmIgk, CD33, SIgM, CD117, IgM Lambda, CD9,
CD13, CD22, CD24; Cytoplasmic IgMKappa, NuTdT; In
addition to CD45, CD19 and CD34 as backbone
markers. The 19 markers panel was evaluated in all pa-
tients to confirm the diagnosis and after chemotherapy
induction treatment to establish the Minimal Residual
Disease.
Isolation of leukemia cells
Preparation of mononuclear cell suspensions from diag-
nostic BM aspirates or PB were made by density-gradient
centrifugation (Lympho prep, Lonza) within 24 hours after
sample obtaining. The blast population was separated with
magnetic microbeads coated with either anti-CD19 or
anti-CD34 antibodies followed by column enrichment
using standard procedures and MACS (Miltenyi, Bergisch
Gladbach, Germany). Purified cells were then stained with
CD34-PERCPCy5.5, CD45-V500 and CD19-PECy7 labeled
antibodies to evaluate the purity of isolated cells. Data
acquisition was performed in a FACSCanto II flow
cytometer-Becton/Dickinson Biosciences (BDB, San Jose,
CA) using the FACSDiva software program and the Infini-
cyt (Cytognos SL, Salamanca, Spain) software program was
used for data analysis. The purity of the isolated tumoral
cells was at least 90 %. Purification of CD34+ cells was per-
formed also in normal BM.
RNA isolation
Total RNA from purified leukemic cells was isolated
using the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s protocols. RNA was quantified by Nano-
Drop ND1000 Spectrophotometer (Thermo Scientific,
Wilmington, USA) at 260 nm wavelength and the quality
was checked using the 2100 Bioanalyzer (Agilent Tech-
nologies). Twenty-seven RNA samples Patient’s with
RIN ≥7 were used for microarrays experiments.
RNA labeling for microarrays
Three hundred Nanograms (300 ng) of total RNA were
used as the input to produce biotin-labeled cRNA for
expression analysis using the TargetAmpNano Labeling
Kit for Illumina Expression BeadChip (Epicentre). Ac-
cording to the protocol supplied by the manufacturer, to
synthesize biotinylated cRNA, total RNA was reverse-
transcribed to cDNA using a T7 oligo(dT) primer. A
second-strand of cDNA was synthesized, transcribed in
vitro, and labeled with biotin-NTP. After purification
with RNeasy Mini Kit (Qiagen) columns, the cRNA was
quantified using NanoDrop.
Microarrays for gene expression profiling
Microarray analysis was performed and analyzed at the
Stanley S. Scott Cancer Center’s Translational Genomics
Core at LSUHSC. Seven hundred fifty Nanograms (750
ng) of labeled cRNA were hybridized at 58 °C for 16 h
to the HumanHT-12 v4 Expression BeadChip (Illumina)
which contains more than 47.000 probes interrogating
more than 34.000 transcripts following the manufac-
turer’s instructions (Illumina, Inc., San Diego, USA).
After washing and staining with streptavadin-Cy3, the
chip was scanned with the BeadArray Reader (Illumina
Inc.) The arrays were analyzed using the Illumina’s Gen-
omeStudio software as has been described before by
Kim SH [34] and Dai L [35]. Briefly, the signals were
normalized using the cubic spline algorithm [36] and the
background signal was removed using the Detection P-
value algorithm that uses the signal of irrelevant probes
(with no target in the human transcriptome) but ther-
modinamically similar to the probes targeting human
targets. Differential expression was determined by com-
paring the condition group (no response to induction
therapy) and the reference group (response to induction
therapy) using the Illumina Custom algorithm. The
microarray experiments were performed in triplicates for
each sample and average values were used for analysis.
Accession number of microarray data deposited in Gene
Expression Omnibus (GEO) is GSE76349.
Real time-PCR validation
cDNA was synthesized from total RNA using Super-
Script III First-Strand Synthesis SuperMix Kit (Invitro-
gen) according to the manufacturer’s procedures.
TaqMan probes were used to quantify the levels of
mRNA expression of candidate genes obtained by
microarray analysis (Assay IDs: ID3 Hs00954037_g1;
ID1 Hs03676575_s1; CMTM8 Hs00418243_m1; IGJ Hs
00950678_g1; RGS1 Hs01023772_m1; RPS4Y1 Hs00
606158_m1; AGAP1 Hs00963817_m1). The reaction was
amplified in a QuantStudio 12 K plex Real-Time PCR
machine (Applied Biosystems). The 2-ΔΔCT method was
used to estimate the fold induction of each gene using
GAPDH and an internal calibrator as controls. Water
was used as a negative control. Assays were done in
triplicate.
Statistical analysis
GraphPad graphic software was used to compare the ex-
pression levels of the genes between the two groups using
Mann Whitney test. Clustering analyses and heatmaps
were performed using R-project (www.r-project.org), Gen-
omeStudio (Illumina) and Gene set Enrichment Analysis
(GSEA, http://software.broadinstitute.org/gsea/index.jsp).
Signaling pathway analysis was done in Metacore and
Metacore KPA. Survival analyses were estimated by
Kaplan-Meier curves and differences between the survival
functions were assessed with the log-rank test. Statistical
analysis was performed using SPSS software (version 22
for windows) and R. p-values that were <0.05 were
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considered statistically significant. EFS was calculated
from the date of trial enrollment to the date of first event
(induction failure, relapse or death). OS was measured
from the date of study entry until the date of death.
Results
Patient characteristics
This study included 43 adult patients newly diagnosed
with Common and Pre-B B-precursor acute lympho-
blastic leukemia (B-ALL). Additional file 1: Table S1 de-
scribes the clinical and molecular characteristics of the
patients. Chromosomal alterations were found only in 5
patients. The number of male and female patients was
similar; the median age was 30 years and the median tu-
moral infiltration at diagnosis determined by flow cy-
tometry was 82 %. The overall outcome of the patients
in this cohort was very poor with a median OS of 11
months and 2-years EFS of 58 %. We defined 24 months
as a period of follow-up from date of patient’s inclusion
to the study.
Unsupervised hierarchical clustering
Microarrays experiments were made in 27 of the 43 pa-
tient samples. Gene expression data was first analyzed by
unsupervised hierarchical clustering. As shown in Fig. 1a,
the normal bone marrow samples (red) were clustered to-
gether and separated from samples from patients diag-
nosed with B-ALL. Out of the 27 samples included in the
microarrays 3 were positive for BCR-ABL–rearrangement
and clustered together (blue). In addition, 4 of 5 patients
who failed to achieve CR after induction treatment (black)
grouped together. It is noteworthy that BM sample of
patient BRO001 who did not achieve CR (with a blast
percentage of 44 % at the end of induction treatment),
grouped together with BRO001_MRD (underlined sam-
ple) which corresponds to tumoral residual sample after
induction treatment.
Identification of gene expression profile associated with
response to therapy
Supervised analysis was used to identify genes that dis-































































Fig. 1 Gene expression profiles of 27 B-ALL bone marrow diagnostic samples. a Unsupervised hierarchical clustering is able to differentiate between
B-ALL patients. Hierarchical clustering analysis in bone marrow diagnostic samples from 27 adult B-ALL patients revealed 3 main groups included the
normal bone marrow grouped together and separately from patient samples. Each square represents 1 sample, each row represents 1 gene. Above,
cluster dendrogram of the bone marrow samples. Red square, Normal BM; black square, patients who did not achieve complete remission; blue square,
patients with BCR-ABL translocation; grey square, patients who achieve complete remission. b Expression analysis of good versus poor induction treatment
response patients. Analysis of gene expression from 5 patients who did not respond to induction therapy (yellow) and 22 patients who achieved complete
remission (grey and blue). The hierarchical clustering identified 442 genes differentially expressed between both groups with p < 0.05. Gene Set Enrichment
analysis was used to construct the heatmap showing the top 50 differentially expressed genes. Samples are shown in columns and gene sets are in rows.
Increasing (red) or decreasing (blue) gene expression is shown relative to the median (black) for each gene. c Signaling pathway analysis using MetaCore
revealed activation of different key hubs with p < 0.005 in patients with poor response to induction therapy. The total 442 differentially expressed genes
were used for pathway analysis. The pathway with the highest activity and involving more of the input genes is the NF-kB signaling. Other signaling
pathways like CD40L, IL-9, JAK1, IL-22 appears to be activated in this group of patients. Strong color represents activation key hub (red arrow) or inhibited
key hub (blue arrow)
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from responders (n = 22, grey and blue squares in
Fig. 1a) to induction treatment. Our analysis identified
442 genes differentially expressed between the two
groups (Fig. 1b shows the first 50 differentially expressed
genes). After applying additional filters (p < 0.05 and
fold change > 2) we selected the top 99 genes that dis-
tinguished non-responder from responder patients.
From this group of genes, 31 were overexpressed in
non-responder patients and 68 were over expressed in
responder patients to induction treatment. In the non-
response group there was a predominant overexpression
of genes involved in self-renewal, differentiation, neo-
plastic transformation (ID3, ID1), B cell development
(IGJ), migration and metastasis (PLAU), B cell activation
(CD83) and oncogenesis (GFI1). This pattern suggests a
more impaired differentiation and more aggressive be-
havior in B-ALL cases that did not respond to therapy.
The complete set of differentially expressed genes is
listed in Additional file 2: Table S2.
We conducted a signaling pathway analysis in Metacore
and Metacore KPA using the 442 differentially expressed
genes from the two groups of patients. As shown in Fig. 1c,
we identified molecular pathways that are aberrantly regu-
lated in the non-response versus the good response group.
Among 442 genes, those involved in Nuclear Factor kappa
B (NF-kB) signaling are specifically activated in the group
of patients who failed to induction chemotherapy treat-
ment. The main alterations in the poor response patients
include activation of the kinase complex IKK that phos-
phorylates I-kB proteins inducing their degradation and
NF-kB p50/p65 translocation to the nucleus where it up
regulates expression of numerous genes involved in cell
survival, proliferation, apoptosis, inflammation, immune
response and invasion. Interestingly, in the poor response
group both NF-kB subunits p50 and p65 are activated. It
is noteworthy that molecules that promote NF-kB signal-
ing, including PKA-cat alpha, TBK1 and MSK1, are also
activated. Other top dysregulated pathways in non-
responders are involved in lymphocytes proliferation as
JAK1 and CD40L signaling and others are involved in
anti-apoptosis as pathway generated by IL-9. We also
found high activity of c-jun oncogene in this group of pa-
tients. All dysregulated pathways derived from non- re-
sponders group, are shown in Additional file 3: Table S3.
We also identified molecular interactions and dysregu-
lated pathways in the responders group that could be
contributing to successful treatment in these patients.
As shown in Additional file 4: Table S4, p53-dependent
apoptosis is among the 4 dysregulated key pathway in
the remission group. The expression of the TP53 gene is
16 % increased in this group as compared to the no
remission group (data not shown). The pathways dysreg-
ulated in the 2 groups (Additional files 5 and 6), are
strongly implicated in regulation of leukemic cell
functions and several pathways are well known for their
role in tumoral development, progression and treatment
resistance of different types of leukemia [37–42]. Thus,
global pathway analysis allowed us to identify critical
biological networks altered in chemotherapy resistant
patients.
Stratification of risk according to gene expression patterns
Using unsupervised hierarchical cluster analysis of the
top 99 discriminating genes, the samples were sepa-
rated into three major groups (Fig. 2a). Comparing
the clinical characteristics of these groups we found
statistically significant differences for age (p = 0.049),
White Blood Cell Count (WBCC) (p = 0.025) and tu-
moral load in PB at diagnosis (p = 0.008). We also
found a different trend in hemoglobin, platelets, and
tumoral load at diagnostic between groups 1 and 3
(Table 1) located both extremes of heatmap. Group 3
(green bar) included patients who achieved complete
remission (6/6), whereas group 1 (red bar) included
5/9 patients with failure to induction therapy. We in-
creased the stringency of the analysis (p < 0.03, fold
change >3) and found 20 genes that were able to
identify the previous same groups in an unsupervised
analysis (Fig. 2b). Taken together, our results suggest
that gene patterns can be correlated with biological
features and can distinguish good and bad prognostic
groups in our population.
Evaluation of the clinical impact of gene expression
profile associated with prognosis
To evaluate the clinical impact of our gene expression
analysis, we examined the survival of patients in the two
risk groups defined by their gene expression profile
(group 1 and 3). As can be seen in Fig. 2c and d, there is
a statistically significant difference in EFS (log-rank test
p = 0,001) and OS (log-rank test p = 0,012) between the
2 groups. Considering that groups 1 and 3 established by
gene expression profile are different in terms of other
variables that can strongly predict the prognosis of
disease including WBCC (group 1 > 30 000/uL and
group 3 < 30 000/uL), age at diagnosis (group 1 > 30
and group 3 < 30 years old) and also in EFS and OS, we
defined these two groups as predicted good and poor
prognosis groups (PGP and PPP, respectively).
Confirmation analysis by Real-time quantitative PCR
To confirm the results of our microarray analysis, we
selected the 7 most differentially expressed genes
(CMTM8, ID3, IGJ, RGS1, RPS4Y1, CENTG2, ID1) be-
tween the responder versus non-responder groups
and analyzed their expression by semi-quantitative
RT-PCR in 43 samples (27 initially included in the
microarray analysis plus 16 new samples). As shown
Cruz-Rodriguez et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:64 Page 5 of 14
in Fig. 3a, there was a significant correlation between
the microarray data and RT-PCR for the expression
of the 7 validated genes. Figure 3b shows the expres-
sion of our 7 genes profile determined by microarrays
and RT-PCR in our good and poor prognosis groups.
As can be seen, CMTM8, ID1, ID3 and IGJ are highly
expressed in the bad prognosis group, whereas
CENTG2, RGS1 and RPS4Y1 have lower expression in
this group of patients and these results are consistent
both by microarrays and PCR assays. Taken together,
these results support the validity of the expression
data obtained by microarrays for this set of 7 genes.
Validation of gene expression profile for predicting outcome
Figure 4a shows the heatmap and dendrogram for the
unsupervised cluster analysis applied to 43 patients ac-
cording to the expression of our 7 genes signature. Inter-
estingly, we found 2 different groups with different gene
signatures. The therapy response rate was significantly
higher in group 1 (green) than in groups 2 (red) (94 %
vs. 60 % respectively) and each group included the same
patients classified before as PPP and PGP (respectively)
according to microarray analysis (Figs. 2a and 4a). As
can be seen in Fig. 4b, for most of the genes (ID1, ID3,



















































































































































P= <0.001 P= 0.012
Fig. 2 Hierarchical clustering and survival curves of the 27 B-ALL patients based on expression of top selected genes in responding vs. no responding
analysis. a Top 99 genes providing the biggest expression differences between good and poor response. p < 0.05 and fold change >2 were used to
cluster the 27 B-ALL patients. b Distribution of 20 selected genes in B-ALL from list of 99 genes more differentially expressed between responders and
no-responders to induction treatment. Genes with p < 0.03, fold change >3 were selected to cluster the 27 B-ALL bone marrow samples. Clustering
analysis shows that set of 20 genes can distinguishes the same 3 groups identified with our list of 99 genes candidate predictors of response to therapy
(blue, red and green bars). Kaplan Meier curves for EFS (c) and OS (d) in good and poor prognostic groups according to gene expression profile. Twenty-
seven patients were assigned to either predicted good prognosis group (PGP) or predicted poor prognosis group (PPP) based on
expression of 99 differentially expressed genes between responders and non-responders to induction therapy
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Table 1 Association of expression profiles with high impact prognosis variables
Variable Group 1 Group 2 Group 3 P-value
(n=6) (n=12) (n=9) (Group 1 vs Group 3)
Age - years
Median 30 29 21 0,049*
Range 19–63 19–50 16–30
White blood cell count/ul
Median 45800 10075 6105 0,025*
Range 1940–412900 1410–170100 1.490–35.970
Hemoglobin (g/dl)
Median 7.6 8.85 9.8 0,114
Range 4.15–13.7 5.1–11.5 6.4–13.5
Platelet count/ul
Median 27900 15500 140550 0,27
Range 6900–682000 6000–84000 6000–474000
Bone Marrow blast count in myelogram- (%)
Median 95 93 84 0,45
Range 61–97 80–97 74–98
Bone Marrow blast count in Flow cytometry- (%)
Median 91 90 80 0,28
Range 36–95 54–95 40–95
Peripheral blood blast count/uL
Median 41910 173.45 0 0,008*
Range 0–210600 0–124.000 0–2.500
Complete remision- no. Patients
Achieve 4/9 12/12 6/6
Non achieve 5/9 0/12 0/6
* indicates statistical difference
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Fig. 3 Correlations of expression data between microarrays and RT-PCR. a Spearman’s correlation plots show a positive correlation between data
obtained by microarrays and RT-PCR. b The expression obtained by RT-PCR is consistent with microarrays data for all 7 evaluated genes. CMTM8,
ID1, ID3 and IGJ shows an increased expression in bad prognosis group, whereas CENTG2, RGS1 and RPS4Y1 have low expression in this prognostic
group in both techniques
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differences (p < 0.05) in their expression between the 2
clustered groups. Both EFS and OS of patients with the
predicted poor prognosis signature were significantly
shorter than those of the subgroup of patients with a pre-
dicted good prognosis signature. Fig. 5a and d show the
Kaplan-Meier curves for the predicted prognosis groups
based on RT-PCR data (P = 0,007 for EFS and 0,007 for
OS). As can be seen, the OS predictive power of our gene
signature is better with 7 genes than with 99 (Figs. 2d and
5d). As clinical variables such as high WBCC and age at
disease onset have been reported to be strongly associated
with outcome in B-ALL [19], we also evaluated these con-
ventional variables for predicting outcome in our patients
in order to compare their predictive power with our gene
expression profile variable. As shown in Fig. 5b, and d for
WBCC and 5C and 5 F for age, although older patients
and those with high WBCC have worse EFS and OS, the
difference was not statistically significant and both con-
ventional parameters appear to be less predictive than our
gene expression signature.
Given the consistency of the results obtained by the
two methods, we propose that our 7 genes signature
could be a potential prognostic factor for the better
stratification in risk groups of adult Colombian patients
with B-ALL.
Prognostic impact of ID1/ID3/IGJ expression signature in
the context of other clinical and molecular parameters
We performed correlation analysis in order to determine
which of our 7 genes were the most influential in the prog-
nosis and outcome of patients. Significant correlations were
found only between the overexpression of ID3, IGJ and ID1
with the presence of event (p = 0.001, 0.015 and 0.017
respectively), and non-CR achievement (p = 0.002, 0.010,
0.019 respectively). ID3 and IGJ overexpression were
significantly correlated with poor EFS (p = 0.003, 0.001
respectively). Overexpression of IGJ tended to correlate
with worst OS (p = 0.057). According to the potential prog-
nostic value of ID1, ID3 and IGJ, we used a multivariate
model analysis with our gene profile in addition to other
A B





































































































Fig. 4 Validation of gene expression profile for outcome prediction. a Unsupervised hierarchical clustering analysis applied to 43 patients according to the
expression of our 7 genes signature for prognosis prediction. Expression of selected 7 prognostic relevant genes determined by RT-PCR was used to cluster
all 43 patients included in the study. Unsupervised cluster distinguished 2 groups of samples (red, bad prognosis; and green, good prognosis). b Expression
of 7 genes for prognosis prediction in the 2 clustered groups (red and green bars in Figs. 1a and 4a) determined by RT-PCR. Results were normalized
against the expression level of GAPDH. High expression of ID3, IGJ, ID1 and CMTM8 was shown to be associated with predicted poor prognosis (PPP)
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factors significantly associated with prognosis in univariate
analysis for this cohort (clinical and molecular variables
with p < 0.1 in univariate analysis were entered into multi-
variate model) to evaluate if simultaneous overexpression
of ID1, ID3 and IGJ is an independent prognostic param-
eter for event risk, CR achievement, EFS and OS. Our gene
profile was an independent prognostic parameter for CR
achievement, presence of event, EFS and OS in a multivari-
ate model including only clinical variables obtained previ-
ous to induction treatment. We also found that our gene
profile is an independent prognostic parameter for CR
achievement, presence of event and low EFS when we in-
clude in our multivariate model the MRD detection vari-
able, which is the most important predictor currently used
(Table 2). As can be seen in Fig. 6a and b, patients with
high expression of only ID1, ID3 and IGJ genes at time of
diagnosis, showed significantly shorter EFS and OS
(p = 0.001 for EFS and 0.001 for OS). Interestingly,
this 3-gene prediction of disease outcome is even
better tan previoulsy observed with 7 genes (Fig. 5a
and d).
Discussion
The main objective of this study was to understand the
biology and behavior of B-ALL specifically in a Colombian
sample and set the bases for future research of this kind in
Hispanic population in order to identify a gene expression
signature that may have prognostic value. Given that one
of the challenges in the treatment of ALL is to facilitate
the development of more appropriate therapeutic ap-
proach, the development of new genetic prognostic factors
are needed to increase the accuracy of risk stratification.
An improved and more accurate patient classification in
risk groups with similar clinical outcome would help to
devise new strategies for the identification of patients at
higher risk to improve their benefits to allogeneic trans-
plant; in addition, those patients with a more favorable
prognosis and with less risk of relapse would be helped by
receiving less intensive treatment reducing the toxicity
and death associated with therapy.
We have identified a set of 442 differentially expressed
genes able to distinguish patient subsets with different re-
sponse to chemotherapy induction treatment. Within the
set of genes, we found high expression levels of genes ID1,
ID3, IGJ, CMTM8 in the group of patients with the worst
outcome. Interestingly, some of these genes have been
associated with leukemia and other tumors. For example,
ID family genes such as ID1 and ID3 have found to be
deregulated in many types of human tumors and contrib-
ute to processes such as tumorigenesis, tumor progres-
sion, angiogenesis, cell migration, epithelial mesenchymal
transition and stem cell renewal [43–55]. The gene IGJ,
which we found also overexpressed in the poor response
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Fig. 5 Kaplan Meier survival curves for good and poor prognostic groups according to gene expression profile, WBCC and age. Forty-three patients
were assigned to either predicted good prognosis group (PGP) or poor prognosis group (PPP) based on expression of 7 differentially expressed genes.
EFS (a) and OS (d) in predicted groups. Impact of WBCC count at diagnosis on EFS (b) and OS (e). Impact of age at diagnosis on EFS (c) and OS (f)
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signature in pediatric patients with B-LLA with the
worst 4 years-event free survival, high frequency of
positive MRD and high Latin Hispanic ethnicity [32].
The gene CMTM8 is reported as a candidate tumor
suppressor gene in an osteosarcoma tumor model
suppressing the activity of the oncogenic proteins c-Met
and GPR177 [56], however, its role in hematological
tumors has not been reported.
Other genes showing altered expression in the poor
response group included CENTG2 (AGAP1), RPS4Y1
and RGS1. Interestingly, CENTG2 has been reported to
have dual roles in susceptibility to disease due to its
association with a bad prognostic signature in B-ALL in
children [32], but having a protective role in gastric
cancer [57]. On the other hand, RGS1 that consistent
































Duration of Event Free Survival (Months) Duration of overall survival (Months)
Fig. 6 Kaplan Meier curves according to the presence of high risk expression profile. Event free survival (a) and Overall Survival (b) of
patients with simultaneous low ID1/ID3/IGJ expression (green line) vs. patients with simultaneous high ID1/ID3/IGJ expression (red line)
Table 2 Prognostic impact of ID1/ID3/IGJ expression signature in the context of other clinical and molecular parameters
Univariate model Multivariate model pre-treatment variables Multivariate model pre-treatment variables and MRD
Parameter p Value OR (95 % CI) p Value OR (95 % CI) p Value OR (95 % CI)
EVENT
Gene profile 0.029 6.57 (1.217–35.529) 0.029 6.57 (1.217–35.529) 0.029 6.57 (1.217–35.529)
Age >30 0.052 3.48 (0.990–12.242) 0.120 2.86 (0.759–10.779) 0.405 1.89 (0.420–8.553)
WBCC >30.000/ul 0.090 4.09 (0.803–20.870) 0.315 2.10 (0.494–8.932) 0.152 3.55 (0.628–20.118)
MRD 0.077 4.05 (0.859–19.085) 0.114 3.29 (0.752–14.452)
COMPLETE REMISSION
Gene profile 0.016 6.48 (1.413–29.713) 0.016 6.48 (1.413–29.713)
Sex 0.092 0.14 (0.016–1.366) 0.313 0.43 (0.089–2.170)
EVENT FREE SURVIVAL
Gene profile 0.004 3.58 (1.493–8.597) 0.004 3.58 (1.493–8.597) 0.017 3.08 (1.223–7.759)
Age >30 0.056 2.40 (0.979–5.922) 0.139 2.00 (0.799–5.027) 0.533 1.37 (0.504–3.760)
MRD <0.001 1.00 (1.001–1.004) <0.001 1.002 (1.001–1.003)
OVERALL SURVIVAL
Gene profile 0.008 3.97 (1.439–111.000) 0.029 3.21 (1.127–9.176) 0.122 2.41 (0.789–7.408)
Platelets count 0.002 1.00 (1.000–1.000) 0.015 1.00 (1.000–1.000) 0.002 1.00 (1.000–1.000)
Age >30 0.060 4.08 (0.944–17.655) 0.025 4.32 (1.204–15.550) 0.060 4.08 (0.944–17.655)
t(9;22) 0.076 0.08 (0.005–1.298) 0.327 0.34 (0.040–2.927) 0.076 0.08 (0.005–1.298)
MRD <0.001 1.00 (1.002–1.005) <0.001 1.00 (1.002–1.008)
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gene expression risk group with the poorest outcome
described by Kang et al in a children B-ALL population
[58]. In addition, RGS1 encodes a member of the regula-
tor of G-protein signaling family. This protein is strongly
expressed in immune cells including germinal center B-
lymphocytes, T lymphocytes, natural killer cells, den-
dritic cells and monocytes. At functional level, RGS1
regulates T-cell migration and B cell homing to lymph
nodes in response to chemokines signaling (CXCL12
and CCL19) [59]. Additionally, while the function of
RPS4Y1 is not well described and has no prior link to
leukemia, this gene could have a possible role in
leukemogenesis based on known functions identified in
other models of cancer stem cells resistant to radiation
which presents more than 5-fold reduction in the ex-
pression of RPS4Y1 [60].
Finally, our set of 3 genes (ID1, ID3 and IGJ) was
able to characterize all patients in risk groups,
whereas other molecular and clinical prognostic vari-
ables including age, WBCC and BCR-ABL transloca-
tion showed no clinical impact. Importantly, our
results support the fact that it could be possible to
use gene expression profiling to predict the outcome
of all patients at the time of diagnostic regardless of
whether or not they have chromosomal rearrange-
ments. In addition, although the detection of MRD is
currently the variable that can predict with greater
certainty the prognosis, this determination is made
after induction treatment and there are still a high
number of patients who die by the high toxicity of
induction therapy because of the lack of correct risk
stratification. Considering this, it is important to
highlight that our 3-gene signature is the independent
prognostic parameter with the highest impact between
all pre-treatment variables included in our multivari-
ate model. Interestingly, the ID genes, which are sig-
nificantly implicated in the outcome of our patients,
have been reported in other models of cancer as pro-
moters of cell survival and have been associated with
the up-regulation of anti-apoptotic pro-survival fac-
tors through activation of NF-kB signaling pathway
[43], which represents the signaling pathway most ab-
errantly regulated in the non-response group (Fig. 1c).
In addition, some studies have reported that transfec-
tion of head and neck squamous cell carcinoma
(HNSCC) cells with ID1 in vitro induced the phos-
phorylation of Akt (p-Akt) via phosphoinositide
kinase-3 (PI3K) and increased the expression of survi-
vin via NF-κB [61]. This evidence represents a
possible mechanism that might explain the chemo-
resistance and poor survival of our patients and also
represents a potential opportunity to evaluate the
effect of the alteration of our 3-gene signature in the
NF-κB signaling pathway. Altogether, these data
suggest that simultaneous high expression of ID1, ID3
and IGJ could be associated with poor prognosis in
Hispanic adult B-ALL due to its potential to increase
tumor cell survival possibly through NF-kB signaling.
Gene expression profiles associated with prognosis
have been reported in B-ALL [26, 32, 62]. However most
studies are focused on this population since the inci-
dence of this disease is higher in this age group. The fact
that there are great differences in genetic and molecular
characteristics between adults and children with B-ALL
may explain the existence of large differences regarding
prognosis. This highlights the need to increase the effort
on research directed towards the identification of mo-
lecular markers underlying the different outcome of B-
ALL in adult patients.
We have to admit the existence if certain limita-
tions in our results. In this study we used a small
number of patients due to several difficulties such as
the low incidence of this disease in Colombian adult
population and also due to both, the multiple barriers
that patients have to access health care and the lack
of cancer centers that are needed for the establish-
ment and accurate diagnosis and a prompt treatment.
Therefore, the number of patients with B-ALL con-
firmed diagnosis is small and perhaps for this reason
there are no studies about the molecular biology of
the disease in Hispanic patients. Our prospective
study was conducted including all patients who vis-
ited the hematology service for 2 years at the Na-
tional Cancer Institute of Colombia, which is the
biggest cancer reference center in our country and
also in the hospital Universitario San Ignacio, one of
the largest cancer centers in the Country. Even
though because of the small number of patients in-
cluded in our study, our results should be interpreted
with caution and await validation in an independent
larger cohort. In addition, due to the large genetic
variation in Hispanic populations we cannot extrapo-
late our results to other Latin American Countries.
Similarly, comparison and validation of our results in
different ethnic groups, including African Americans
and Caucasians with B-ALL would support the role of
these genes in the pathogenesis of the disease. The
study of the response to induction therapy and
clinical outcome in different ethnic groups is war-
ranted by the differential response to the treatment
associated with ethnicity [9–14]. Even though it is not
possible to ensure that Hispanic patients, specifically
Colombians, have a worse response and poorer out-
come due to biological characteristics inherent to our
population, is interesting that even after following the
same scheme of treatment, the survival varies greatly
by population. So far, ethnic differences in survival of
childhood ALL have been reported in many studies,
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with poorer survival observed among African Americans
or those with Hispanic ethnicity when compared with
European, Americans or Asians [63–69]. However, up to
this moment, the role of ethnicity to the therapy in adults
with B-ALL has not been studied. Therefore, it would be
interesting to explore whether these differences are due to
differences in biological characteristics of patients or due
to differences in the chemotherapeutic schemes.
Despite these limitations of our study, we believe it is
important that developing countries begin to assess the
biology of the disease in their patients. We have de-
scribed for the first time the transcriptional basis of
adult B-ALL in our population, which reflects molecular
differences between B-ALL cases with good and poor re-
sponse to induction chemotherapy. In addition, our
comprehensive analysis suggests the basis for future
functional analysis that may lead to new potential targets
for the treatment of B-ALL, including ID gene family,
which has been associated with chemo resistance in dif-
ferent models of cancer.
Conclusions
Overall, our data suggest that high expression of ID1,
ID3 and IGJ genes is associated with failure to induction
treatment and poor prognosis in adult B-ALL. These
analyses identified a subset of high-risk B-ALL adult pa-
tients who may benefit from new emerging target ther-
apies or personalized chemotherapy approaches. In
addition, assessment of the expression levels of this rela-
tively small number of genes could be easily translated
into a clinically useful and inexpensive assay, which
could be quite important in developing countries with
precarious health systems.
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